
Murat O Arcasoy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1386607/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. European Respiratory Journal, 2014, 44, 178-187.	6.7	161
2	Outcomes of Allogeneic Hematopoietic Cell Transplantation inÂPatients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biology of Blood and Marrow Transplantation, 2016, 22, 432-440.	2.0	127
3	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood, 2019, 134, 1498-1509.	1.4	123
4	Expression of erythropoietin receptor splice variants in human cancer. Biochemical and Biophysical Research Communications, 2003, 307, 999-1007.	2.1	109
5	<i>ZCCHC8</i> , the nuclear exosome targeting component, is mutated in familial pulmonary fibrosis and is required for telomerase RNA maturation. Genes and Development, 2019, 33, 1381-1396.	5.9	85
6	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Advances, 2020, 4, 4282-4291.	5.2	77
7	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	5.2	63
8	Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clinical Cancer Research, 2005, 11, 20-7.	7.0	58
9	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). Blood, 2018, 132, 577-577.	1.4	39
10	The clinical and laboratory evaluation of the patient with erythrocytosis. European Journal of Internal Medicine, 2015, 26, 297-302.	2.2	33
11	Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients. Blood, 2018, 132, 4282-4282.	1.4	7
12	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. Blood, 2018, 132, 3032-3032.	1.4	6
13	A novel nucleotide substitution in the 5′ untranslated region of ANKRD26 gene is associated with inherited thrombocytopenia: a report of two new families. Annals of Hematology, 2019, 98, 1789-1791.	1.8	4
14	Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings. Blood, 2019, 134, 2943-2943.	1.4	4
15	Pregnancy in patients with thrombocytopenia and absent radii (TAR) syndrome. Annals of Hematology, 2017, 96, 1589-1590.	1.8	2
16	Arterial thrombosis and second cancer in MPNs. Blood, 2020, 135, 301-302.	1.4	2
17	Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era. Blood, 2020, 136, 52-53.	1.4	1